ESR2 and depressive disorder: In conclusion, long-term oral treatment of young OVX mice with a novel, highly selective ERβ agonist, EGX358, reduced drug-induced vasodilation and enhanced spatial and object recognition memory without adverse effects on anxiety-or depression-like behaviors, body weight, or overall health.